Chris H. Bangma

17.6k citations

213 papers · 9.9k indexed · 2 hit papers · h-index 56

Pulmonary and Respiratory Medicine top 0.1%
Surgery top 1%
Oncology top 1%
Molecular Biology top 5%
Rheumatology top 0.5%

Co-authors: Monique J. Roobol Fritz H. Schröder Ewout W. Steyerberg Roderick C.N. van den Bergh Antti Rannikko Theodorus van der Kwast Ries Kranse Xiaoye Zhu
Topics: Prostate Cancer Diagnosis and Treatment (151 papers)Prostate Cancer Treatment and Research (140 papers)Bladder and Urothelial Cancer Treatments (48 papers)
Cited by: Pulmonary and Respiratory Medicine Urology Rheumatology
Journals: Nature Medicine JNCI Journal of the National Cancer Institute Cancer
Partner nations: Netherlands United States Canada

In The Last Decade

Chris H. Bangma

203 papers receiving 9.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study

2012 411 citations Meelan Bul, Xiaoye Zhu et al. European Urology profile →
A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment

2016 272 citations Leonard P. Bokhorst, Chris H. Bangma et al. European Urology profile →

Peers

Countries citing papers authored by Chris H. Bangma

Since Specialization

Citations

This map shows the geographic impact of Chris H. Bangma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris H. Bangma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris H. Bangma more than expected).

Fields of papers citing papers by Chris H. Bangma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris H. Bangma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris H. Bangma. The network helps show where Chris H. Bangma may publish in the future.

Co-authorship network of co-authors of Chris H. Bangma

This figure shows the co-authorship network connecting the top 25 collaborators of Chris H. Bangma. A scholar is included among the top collaborators of Chris H. Bangma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris H. Bangma. Chris H. Bangma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study 2025 ·BMC Cancer ·(unknown),Chris H. Bangma,Maarten J. Bijlsma,Alfons C.M. van den Bergh,Lambertus A. Kiemeney,Wietske Kievit,(unknown),Diederik M. Somford,(unknown),Katja K.H. Aben,Igle J. de Jong,Floris J. Pos,(unknown)	1
2	Hereditary and Familial Traits in Urological Cancers and Their Underlying Genes 2024 ·European Urology Open Science ·Kari Hemminki,Lambertus A. Kiemeney,Alicia K. Morgans,(unknown),Renate Pichler,Otto Hemminki,Zoran Čulig,Peter F.A. Mulders,Chris H. Bangma	1
3	Clinicopathological characteristics of glomeruloid architecture in prostate cancer 2020 ·Modern Pathology ·Eva Hollemans,Esther I. Verhoef,Chris H. Bangma,John Rietbergen,Susanne Osanto,Rob C.M. Pelger,Tom van Wezel,Henk G. van der Poel,Elise M. Bekers,Jozien Helleman,Monique J. Roobol,Geert J.L.H. van Leenders	7
4	Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore 2018 ·Urologic Oncology Seminars and Original Investigations ·Jan Verbeek,Chris H. Bangma,Charlotte F. Kweldam,Theodorus van der Kwast,Intan P.E.D. Kümmerlin,Geert J.L.H. van Leenders,Monique J. Roobol	29
5	The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date 2017 ·British Journal of Urology ·Sophie Bruinsma,Liying Zhang,Monique J. Roobol,Chris H. Bangma,Ewout W. Steyerberg,Daan Nieboer,Mieke Van Hemelrijck	40
6	Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer 2015 ·World Journal of Urology ·Lionne D. F. Venderbos,Monique J. Roobol,Chris H. Bangma,Roderick C.N. van den Bergh,Leonard P. Bokhorst,Daan Nieboer,Rebecka Arnsrud Godtman,Jonas Hugosson,Theodorus van der Kwast,Ewout W. Steyerberg	4
7	Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer 2014 ·Modern Pathology ·Charlotte F. Kweldam,Mark F. Wildhagen,Ewout W. Steyerberg,Chris H. Bangma,Theodorus van der Kwast,Geert J. van Leenders	216
8	A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine 2013 ·Clinical Cancer Research ·Raju Kandimalla,Roy Masius,Willemien Beukers,Chris H. Bangma,Torben F. Ørntoft,Lars Dyrskjøt,Nikki van Leeuwen,Hester F. Lingsma,Angela A.G. van Tilborg,Ellen C. Zwarthoff	51
9	Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer 2013 ·European Urology ·Monique J. Roobol,Ries Kranse,Chris H. Bangma,(unknown),B. G. Blijenberg,Ron H. N. van Schaik,Wim J. Kirkels,Suzie J. Otto,Theodorus van der Kwast,Harry J. de Koning,Fritz H. Schröder	91
10	Prostate-specific Antigen–Based Prostate Cancer Screening: Reduction of Prostate Cancer Mortality After Correction for Nonattendance and Contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer 2013 ·European Urology ·Leonard P. Bokhorst,Chris H. Bangma,Geert J.L.H. van Leenders,(unknown),Sue Moss,Fritz H. Schröder,Monique J. Roobol	61
11	Prostate-specific antigen screening can be beneficial to younger and at-risk men 2012 ·Canadian Medical Association Journal ·Monique J. Roobol,Chris H. Bangma,Stacy Loeb	2
12	Disease-Specific Survival of Men With Prostate Cancer Detected During the Screening Interval: Results of the European Randomized Study of Screening for Prostate Cancer–Rotterdam After 11 Years of Follow-Up 2011 ·European Urology ·Xiaoye Zhu,Pim J. van Leeuwen,Meelan Bul,Suzie J. Otto,Harry J. de Koning,Chris H. Bangma,Fritz H. Schröder,Monique J. Roobol	8
13	Markers Predicting Response to Bacillus Calmette-Guérin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review 2011 ·European Urology ·Tahlita C.M. Zuiverloon,Annemieke J.M. Nieuweboer,(unknown),Wim J. Kirkels,Chris H. Bangma,Ellen C. Zwarthoff	142
14	Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle–Invasive Bladder Cancer 2010 ·Clinical Cancer Research ·Tahlita C.M. Zuiverloon,Madelon N.M. van der Aa,Theodorus van der Kwast,Ewout W. Steyerberg,Hester F. Lingsma,Chris H. Bangma,Ellen C. Zwarthoff	83
15	The value of EZH2, p27 ^kip1 , BMI‐1 and MIB‐1 on biopsy specimens with low‐risk prostate cancer in selecting men with significant prostate cancer at prostatectomy 2009 ·British Journal of Urology ·Tineke Wolters,Kees J. Vissers,Chris H. Bangma,Fritz H. Schröder,Geert J.L.H. van Leenders	26
16	The effect of study arm on prostate cancer treatment in the large screening trial ERSPC 2009 ·International Journal of Cancer ·Tineke Wolters,Monique J. Roobol,Ewout W. Steyerberg,Roderick C.N. van den Bergh,Chris H. Bangma,Jonas Hugosson,Stefano Ciatto,Maciej Kwiatkowski,Arnauld Villers,M. Luján,Vera Nelen,Teuvo L.J. Tammela,Fritz H. Schröder	51
17	Bladder cancer biomarkers and their role in surveillance and screening 2008 ·International Journal of Urology ·(unknown),Chris H. Bangma,Ellen C. Zwarthoff	44
18	A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy 2008 ·Cancer Immunology Immunotherapy ·(unknown),Corrina M.A. de Ridder,(unknown),(unknown),Angus Dalgleish,Stephen Todryk,Chris H. Bangma,Robert Kraaij	11
19	Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells 2005 ·Kidney International ·Marieke S.J. Schepers,(unknown),Chris H. Bangma,Carl F. Verkoelen	85
20	Blood and serum substances for markers of prostate cancer 2000 ·Microscopy Research and Technique ·Chris H. Bangma,Paul C.M.S. Verhagen	8

About Chris H. Bangma

Chris H. Bangma is a scholar working on Pulmonary and Respiratory Medicine, Urology and Oncology, having authored 213 papers that have together received 9.9k indexed citations. Recurring topics across this work include Prostate Cancer Diagnosis and Treatment (151 papers), Prostate Cancer Treatment and Research (140 papers) and Bladder and Urothelial Cancer Treatments (48 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (7.1k citations), Urology (692 citations) and Rheumatology (1.3k citations). Chris H. Bangma has collaborated with scholars based in Netherlands, United States and Canada. Frequent co-authors include Monique J. Roobol, Fritz H. Schröder, Ewout W. Steyerberg, Roderick C.N. van den Bergh, Antti Rannikko, Theodorus van der Kwast, Ries Kranse, Xiaoye Zhu, Tineke Wolters and Mark F. Wildhagen. Their work appears in journals such as Nature Medicine, JNCI Journal of the National Cancer Institute and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact